Trial designs used to study neuroprotective therapy in Parkinson's disease
Authors:
- 23 August 2012
- journal article
- review article
- Published by Wiley in Movement Disorders
- Vol. 28 (1) , 86-95
Abstract
There have been numerous trials conducted to evaluate putative disease‐modifying or neuroprotective treatments in Parkinson's disease. These trials have used several different study designs and outcome measures. Each of these has its own strengths and weaknesses. Confounding all studies is the potential symptomatic benefit that the treatment might have on the features of Parkinson's disease. In addition, patient‐related factors such as age of onset and the nature of the dominant symptoms may have important impacts that are often not addressed. Here we provide an overview of the various trial designs that have been used and emphasize the challenges faced in attempting to study neuroprotection in Parkinson's disease and the advances needed before this goal can be successfully achieved. © 2013 Movement Disorder SocietyKeywords
This publication has 45 references indexed in Scilit:
- Interpreting the results of Parkinson's disease clinical trials: Time for a changeMovement Disorders, 2011
- Rationale for delayed‐start study of pramipexole in Parkinson's disease: The PROUD studyMovement Disorders, 2010
- A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's DiseaseNew England Journal of Medicine, 2009
- Washout and delayed start designs for identifying disease modifying effects in slowly progressive diseases using disease progression analysisPharmaceutical Statistics, 2008
- UPDRS activity of daily living score as a marker of Parkinson's disease progressionMovement Disorders, 2008
- A randomized, double‐blind, placebo‐controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristicsMovement Disorders, 2008
- Tremor dominant parkinsonism: Clinical description and LRRK2 mutation screeningMovement Disorders, 2007
- Timing of treatment initiation in Parkinson's disease: A need for reappraisal?Annals of Neurology, 2006
- The effect of deprenyl and levodopa on the progression of Parkinson's diseaseAnnals of Neurology, 1995
- Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's DiseaseNew England Journal of Medicine, 1993